TTrialPathMatch Me to Trials
← Back to trials
RecruitingDegenerative Joint Disease of Shoulder

Cryoneurolysis of the Suprascapular Nerve for Perioperative Pain Control After Receiving a Reverse Total Shoulder Arthroplasty (RTSA)

Eligible age

30–85 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this research is to find out if a treatment called cryoneurolysis can reduce pain after reverse total shoulder replacement surgery. This treatment uses cold to temporarily block a nerve in the shoulder. The study will compare people who receive the treatment to those who do not, to see if it helps lower pain and reduce the need for opioid pain medications after a reverse total shoulder surgery (RTSA).

Sponsor: North Texas Medical Research Institute, PLLC

You may qualify if…

  • Male patients or female who are not pregnant and do not plan on future pregnancy during trial participation
  • between 30-85 years of age
  • BMI less than or equal to 45
  • Currently setup for an elective primary reverse total shoulder arthroplasty due to primary osteoarthritis
  • Ability to provide informed consent to participate in the clinical trial
  • Ability to understand and communicate in English
  • Willingness to comply with all study procedures

You may not qualify if…

  • poorly controlled comorbidities that would not allow surgical intervention such as poorly controlled diabetes (HbA1C \> 8.0) renal insufficiency (eGFR \<60) poorly controlled CV disease such as CHF that is NYHA class 3 and 4
  • inability to receive the intervention including contraindications:
  • Cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and open and/or infected wounds at or near the treatment site
  • patients with history of total joint infection ever or any infection in the last 6 months
  • ASA score \>3 and Outpatient Arthroplasty Risk Assessment (OARA; medical risk stratification scoring system to help determine day surgery vs inpatient)1 score \> 80.
  • previous cryoneurolysis of the suprascapular nerve-utilization of supplemental/holistic methods specifically for pain control (e.g. cannabidiol). This will be discontinued 30 days prior to RTSA and will not be used during the duration of study participation. This will be evaluated by the Principal Investigator and study team prior to consent.
  • significant anti-coagulation usage (other than aspirin) 7 days prior to treatment
  • CV surgery within the last 6 months

Where it's recruiting

Texas

Rockwall

Source: ClinicalTrials.gov · NCT07125833 · last updated 2025-08-15